YouTube Facebook LinkedIn Google+ Twitter Xingrss  

More Trouble for GSK in China


July 25, 2013 | The New York Times has unearthed more trouble for GlaxoSmithKline in China. In addition to bribery allegations in terms of drug sales, the newly revealed documents suggest corruption in research as well as GSK's Shanghai R&D center. New York Times
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.